Strattera and Atrioventricular block first degree - a phase IV clinical study of FDA data

Summary:

Atrioventricular block first degree is reported as a side effect among people who take Strattera (atomoxetine hydrochloride), especially for people who are male, 2-9 old, have been taking the drug for < 1 month also take Risperdal, and have Epilepsy.

The phase IV clinical study analyzes which people have Atrioventricular block first degree when taking Strattera. It is created by eHealthMe based on reports of 27,428 people who have side effects when taking Strattera from the FDA, and is updated regularly.

What is Strattera?

Strattera has active ingredients of atomoxetine hydrochloride. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 29,324 Strattera users. Check the latest studies of Strattera.

What is Atrioventricular block first degree?

Atrioventricular block first degree (heart block first degree) is found to be associated with 646 drugs and 890 conditions by eHealthMe. Check the latest studies of Atrioventricular block first degree.

On Aug, 08, 2026

27,428 people reported to have side effects when taking Strattera.
Among them, 14 people (0.05%) have Atrioventricular block first degree.

Could Strattera cause Atrioventricular block first degree?

Among these 14 people:

How long have people been on Strattera when they have Atrioventricular block first degree? *

What is the gender of people who have Atrioventricular block first degree when taking Strattera? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Atrioventricular block first degree when taking Strattera? *

What are other drugs people take besides Strattera? *

What are other side effects people have besides Atrioventricular block first degree? *

Nausea (feeling of having an urge to vomit): 1 person, 7.14%
Logorrhea: 1 person, 7.14%
High Density Lipoprotein Decreased: 1 person, 7.14%
High Blood Cholesterol: 1 person, 7.14%
Heart Rate Irregular: 1 person, 7.14%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 1 person, 7.14%
Drowsiness: 1 person, 7.14%
Dizziness: 1 person, 7.14%
Conduction Disorder (serious disorder of the heart not responses proper to impulses): 1 person, 7.14%
Bundle Branch Block (disruption in the normal flow of electrical pulses that drive the heart beat): 1 person, 7.14%

What are the existing conditions these people have? *

Psychomotor Hyperactivity (feelings of extreme restlessness): 1 person, 7.14%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Strattera and have Atrioventricular block first degree?

- Check whether Atrioventricular block first degree is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Strattera:

Strattera (29,324 reports)

Browse all side effects of Strattera:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Atrioventricular block first degree:

Atrioventricular block first degree (646 drugs)

Browse all the conditions that are associated with Atrioventricular block first degree:

Atrioventricular block first degree (890 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atomoxetine hydrochloride (the active ingredients of Strattera) and Strattera (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.